DiaKine Therapeutics Products

Lisofylline (LSF) is a synthetic small molecule with novel anti-inflammatory properties. LSF has demonstrated that it can effectively prevent type 1 diabetes in preclinical models. LSF has shown to improve cellular mitochondrial function and to block interleukin 12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT 4 activation are important pathways linked to inflammation and autoimmune damage to insulin producing cells. Therefore, LSF and the next generation of orally bioavailable immune modulators with a similar spectrum of action, offer the promise of providing a new therapeutic approach to prevent or reverse type 1 diabetes. Studies further indicate that LSF also directly reduces glucose-induced changes in human kidney cells suggesting that LSF and orally bioavailable immune modulators have the potential to treat the complications associated with diabetes.